Este artigo está licenciado sob uma licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.

Você tem direito de:
Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato.
Adaptar — remixar, transformar, e criar a partir do material.

De acordo com os termos seguintes:
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de maneira alguma que sugira ao licenciante a apoiar você ou o seu uso
Não Comercial — Você não pode usar o material para fins comerciais.

Sem restricções adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.

Esta licença está disponível em: https://creativecommons.org/licenses/by-nc/4.0/
PREVALENCE OF CELIAC DISEASE AMONG FIRST DEGREE RELATIVES OF BRAZILIAN CELIAC PATIENTS

Patrícia Lopes de ALMEIDA¹, Lenora GANDOLFI¹, ², Inês Cristina MODELLI¹, Rita de Cássia MARTINS², Rodrigo Coutinho de ALMEIDA² and Riccardo PRATESI¹, ²

ABSTRACT – Background - Several studies have shown that celiac disease, an autoimmune disorder that occurs in genetically susceptible individuals, is highly prevalent among relatives of celiac patients. Aim - To determine the prevalence of celiac disease in a group of first degree relatives of Brazilian celiac patients. Methods - First degree relatives of celiac patients attending the Brasilia University Hospital Pediatric Gastroenterology Outpatient Clinic or the Celiac Disease Investigation Center, Brasilia, DF, Brazil, between March 2001 and November 2004 were invited to undergo serological screening for celiac disease applying the IgA anti-endomysium antibody test (IgA-EMA). All positive IgA-EMA sera underwent a second screening using the IgA anti-tissue transglutaminase antibodies test. Duodenal or small intestinal biopsies were performed in all subjects positive to serological testing. Biopsy samples were classified as type (O) normal, (I) infiltrative, (II) infiltrative hyperplastic, (III) flat destructive, and (IV) atrophic hypoplastic. The final diagnosis was ascertained in subjects showing positive serological tests and a grade I to III small intestinal lesion. Results - Nine new cases of celiac disease were found among the 188 first degree relatives tested (4.8%). Conclusion - The present study confirms the high prevalence of celiac disease among first degree celiac patients’ relatives and reinforces the need of extensive diagnostic screening in this specific group.

HEADINGS – Celiac disease, genetics. Brazil.

INTRODUCTION

Celiac disease (CD) is an immune-mediated disorder that occurs in genetically susceptible individuals in which the ingestion of dietary gluten causes intestinal mucosa inflammation, crypt hyperplasia, and villous atrophy. The disease is associated with human leucocyte antigen (HLA), its primary susceptibility being linked to the presence of HLA-DQ2 and DQ8 haplotypes. However HLA genes contribute with no more than 40% of the risk, undetermined non-HLA genes probably being the stronger determinant of CD susceptibility.(18)

In the last 25 years the emergence of progressively more reliable serological markers, such as anti-gliadin, anti-endomysium(30), and anti-transglutaminase antibodies(29) allowed the precocious diagnosis of atypical or even silent form of the disease and greatly contributed to the widespread acknowledging that the prevalence of CD was higher than previously thought. Presently CD may be considered a global public health problem and one of the most common chronic auto-immune conditions since its estimated figures in Western countries varies between 1% and 2.5%(9, 19).

In South America CD was considered a rare disease and its prevalence in the general population was mostly unknown. The increased interest in this polymorphic disease during the last decade resulted in several screening studies. In Brazil GANDOLFI et al. (10) reported a prevalence of 1:681 (0.14%) in presumably healthy blood donors. In the same geographical region PRATESI et al. (27) studying a group of 4,405 adults and children without gastroenterological complaints attending the laboratory of clinical analysis of a large hospital for routine blood testing encountered a prevalence of 1:293 (0.34%) of biopsy proven CD patients. Other recent screening studies in Brazil also disclosed expressive results. MELO et al. (22) found a prevalence of 1:273 (0.36%) among 3,000 blood donors in Ribeirão Preto city, in the State of São Paulo. PEREIRA et al. (26) screening a population of predominantly European ancestry detected a prevalence of 1:415 (0.24%). OLIVEIRA et al. (25) in the city of São Paulo, also studying a group of 3,000 potential blood donors found a prevalence of 1:214 (0.47%). Expressive results were also obtained by GOMEZ et al. (11) in Argentina. Studying 2,000 adults attending an obligatory prenuptial examination, the authors found a

¹Graduate Program in Health Sciences, University of Brasilia School of Health Sciences; ²Celiac Disease Investigation Center, University of Brasilia School of Medicine, Brasilia, DF, Brazil.
Correspondence: Dr. Riccardo Pratesi – SQN 212 – Bloco F – apt. 605 – 70964-060 - Brasilia, DF, Brazil. E-mail: pratesi@unb.br / riccardop@terra.com.br
prevalence of 1:167 (0.59%). Therefore it becomes evident that prevalence of CD in South America is higher than previously thought and is probably underdiagnosed.

Untreated CD predisposes individuals to several complications, some related to malabsorption, such as osteopenia or iron-deficient anemia (arising from one or more of iron, folate and vitamin B-12 deficiency), and some associated with the underlying autoimmune process, such as type 1 diabetes and thyroiditis. Other reported complications are delayed puberty, early menopause, infertility, miscarriage, depression, and neurological disorders (epilepsy with cerebral calcifications, ataxia, and peripheral neuropathy). However, the most feared complication is the development of malignancy of the gastrointestinal tract, mainly non-Hodgkin lymphoma that is the most probable reason for the increased mortality in non treated celiac patients. 

CD is a familial disorder and families with more than one affected member are common. A higher prevalence of CD among relatives of celiac patients has been demonstrated by several studies (1, 2, 3, 6, 8, 9, 14, 15, 20, 21) fully justifying an active search for undiagnosed CD among this at-risk group.

Two studies, assessing the prevalence of CD among relatives of celiac patients have been previously performed in Brazil. The first, by NUNES et al. (22) disclosed a prevalence of 0.8% among a group of 121 relatives. The main focus of the second study, by KOTZE et al. (23) was to determine specificity and sensitivity of the antidiomysium antibody test performed on cryostatic sections of human umbilical cord, in a group of confirmed celiac patients and their first-degree relatives. Among the 18 serological positive first-degree relatives seven agreed to underwent intestinal biopsy. One of these patients disclosed the characteristic mucosal abnormalities of CD and the remaining six showed only an increased number of intra-epithelial lymphocytes.

The objective of the present study is consequently to determine the prevalence of CD in a group of first degree relatives of biopsy-proven CD patients.

METHODS

The present study was performed according to the Declaration of Helsinki and approved by the School of Health Sciences Ethics Committee. All subjects were informed about the objectives of the study and the eventual necessity of small intestinal biopsy. Informed consent was obtained from adults and from the parents for their children. First degree relatives of CD patients attending the Brasilia University Hospital Pediatric Gastroenterology out-patient clinic or the Celiac Disease Investigation Center, Brasilia, DF, Brazil, between March 2001 and November 2004 were invited to undergo serological screen for CD. The Celiac Disease Center is a weekly walking-in clinic open for diagnosis and follow-up of CD patients, attending both children and adults. The diagnosis of CD patients had been based on the modified European Society of Paediatric Gastroenterology and Nutrition (ESPGAN) criteria (24). All family members were on a gluten-containing diet when serological tests were performed. Each blood samples obtained was centrifuged and the resulting serum was stored at -20º until testing. The IgA anti-endomysium antibody indirect immunofluorescent test (IgA-EMA) (25) was used as first-level screening. Briefly, fixed cryostat sections of the distal portions of primate (Cebus apella) esophagus were used as antigen substrate. Fluorescein-labeled goat antibody to human IgA was used as a second antibody. All sera were screened at a dilution of 1/5. The presence of characteristic brilliant green network pattern, under fluorescent light microscope, was considered positive. All positive IgA-EMA sera underwent a second screening, being tested for the presence of IgA anti-tissue transglutaminase antibodies (IgA-tTG) using an ELISA method (Quanta Lite Human tTG IgA — INOVA Diagnostic Inc, San Diego, CA, USA). Optical density was reported in arbitrary unit as a percentage of the optical density of a pool of positive samples, being 20 units the upper normal limit range (cut-off value), as determined by the manufacturer. Duodenal or small intestinal biopsy was recommended to subjects showing positive results to serological testing. Children underwent small intestinal biopsy with a Watson pediatric capsule, samples being taken at the ligament of Treitz. In adults, biopsy samples were obtained through an endoscopy procedure, using an Olympus gastroscope (Tokyo, Japan) with four to five fragments being taken from the second portion of the duodenum. All biopsy specimens were blindly evaluated by a pathologist and a gastroenterologist and classified according to Marsh classification (26) as type 0, normal. Type I, infiltrative pattern, with normal mucosal architecture with increased infiltration of intraepithelial lymphocytes (IELs). In the present study, a count of 25 IELs/100 epithelial cells was taken as the upper limit of the normal range (13, 17). Type II infiltrative hyperplastic, similar to the type I, showing in addition enlargement of the crypts. Type III, flat destructive, characterized by villous atrophy crypt hyperplasia and increased number of IELs. Type IV, atrophic hypoplastic, showing total villous atrophy and hypoplastic criptes. The diagnosis of CD was finally ascertained in subjects showing positive serological tests and a grade I to III small intestinal lesion.

RESULTS

One hundred-eighty-eight first degree relatives (113/60% females and 75/40% males, age range 1 to 75 years, mean age 29.9 years, SD 16.8) out of 307 relatives of 72 CD patients agreed with the screening procedure and, after obtaining informed consent, underwent serological testing. Family members tested included 102 parents (42 fathers and 60 mothers, aged 25 to 75 years, median age 36 years), 76 siblings (31 brothers and 45 sisters, aged 1 to 75 years, median age 11.5 years), and 10 offspring (2 males and 8 females, aged 1-45 years, median age 9.5 years). Positive IgA-EMA was found in 9 first degree relatives (5 sisters, 1 brother and 3 mothers). All nine IgA-EMA positive subjects also showed high levels of IgA-tTG (Table 1) Histological changes characteristic of CD were found in all nine subjects identified by serological testing.
The prevalence of CD among the first degree relatives was 9/188 (4.8%). No positive case was found among the 10 celiac patients’ offspring. The main data concerning the nine biopsy proven CD patient are shown in Table 1.

**DISCUSSION**

It has long been known that symptomatic CD is more frequent among relatives of celiac patients. In view of the probable complications of an undiagnosed and untreated CD, it is important to identify family members, mainly those with a silent form of the disease to offer them the benefit of gluten free diet.

In the present study the prevalence of CD among the first degree relatives was 4.8%. Our results are similar to the result found by FASANO et al. (3) that reported a prevalence of 4.5% new cases among 205 first degree relatives of celiac patients. Previous screening studies based on serological tests, among first degree relatives of celiac patients, have shown appreciable variation in the prevalence of CD. VITORIA et al. (31) in one of the earliest European studies on the subject observed a prevalence of 2.8%, substantially lower than that observed in subsequent studies, in which the prevalence varied between 4.5% (9) to 9.5% (2). These differences could be partially explained by methodological differences in the various studies and by the variability of the genetic background of the distinct population evaluated.

The higher prevalence found among the 76 siblings (7.9%) than among the 102 parents (2.9%), although not statistically significant, follows a tendency observed in other studies in which an increased number of affected siblings was also observed (1, 2, 3, 8, 15).

The prevalence of CD among first-degree relatives dramatically increases when considered only families with two or more cases of CD. In two studies focusing these families the prevalence increases when considered only families with two or more cases of CD. HOGBERG et al. (14) found two new cases of CD among 120 relatives previously screened and considered negative. Among the siblings tested in the present study a female patient that, at the time of her sister CD diagnosis had tested negative became symptomatic and was diagnosed as celiac 5 years later, disclosing positive serological tests and typical abnormalities on duodenal biopsy. The only way to definitely exclude the risk of future CD would be the HLA genotyping confirming the absence of the predisposing alleles, DQA1*0501 and DQB1*0201 (encoding the DQ2 heterodimer), present in approximately 95% of CD patients, and DRB1*04 (associated with the DQ8 heterodimer) found in the remaining 5%. Genotyping, although dependent on a more difficult and expensive technique, would allow the exclusion of a considerable proportion of first degree relatives of CD probands from further screening for CD (9).

Among the nine parents diagnosed as celiac only one patient disclosed symptoms that could be considered as part of the classic manifestations of CD. The remaining patients showed atypical form of the disease and one had no specific complaints. Histopathologic examination of eight biopsy samples disclosed typical abnormalities classified as Marsh III. Only a biopsy sample from an 8 year-old girl with both positive IgA-tTG and IgA-EMA tests showed increased number of IELs as single abnormality (infiltrative type of lesion orMarsh I). Increased number of intraepithelial lymphocytes has been considered typical of CD (12, 20), although no necessarily specific since it can be found in other disorders as, for example, small intestinal bacterial overgrowth (28). In this particular child both serological tests were undoubtedly positive and, in addition, her follow-up revealed a progressive quiescence of her symptoms and normalization of both serological tests after being started on gluten free diet.

In conclusion, the present study, utilizing sensitive and specific serological tests, could identify 9 undiagnosed cases of CD among 188 first degree relatives of 72 celiac patients, confirming the high prevalence of the disease in this specific group. This study corroborates other studies on the same subject (1, 2, 3, 7, 14, 31) and reinforces the fact that relatives of CD patients are a population at high risk of developing gluten intolerance. An extensive screening policy is consequently mandatory in these subjects, especially in members of families in which more than a member is affected.

**TABLE 1. Family connection, age, main symptoms, serological and biopsy results of CD patients relatives identified as celiac**

<table>
<thead>
<tr>
<th>Family connection</th>
<th>Age (years)</th>
<th>Symptoms</th>
<th>IgA-EMA</th>
<th>IgA-tTG</th>
<th>Biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sister</td>
<td>8</td>
<td>Recurrent abdominal cramps, apathy, decreased appetite, mouth ulcers.</td>
<td>+</td>
<td>82.8 U</td>
<td>Marsh I</td>
</tr>
<tr>
<td>Sister</td>
<td>9</td>
<td>Constipation, abdominal distension, bloating.</td>
<td>+</td>
<td>116.4 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Sister</td>
<td>23</td>
<td>No clinical symptoms.</td>
<td>+</td>
<td>213.2 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Sister</td>
<td>43</td>
<td>Irritability, apathy, muscle and joint pain, anemia, osteoporosis.</td>
<td>+</td>
<td>135.5 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Sister</td>
<td>75</td>
<td>Abdominal distension, bloating.</td>
<td>-</td>
<td>-</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Brother</td>
<td>2</td>
<td>Irritability, abdominal distension.</td>
<td>+</td>
<td>246.5 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Mother</td>
<td>25</td>
<td>Frequent diarrhea, abdominal distension, bloating, mouth ulcers.</td>
<td>+</td>
<td>220.2 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Mother</td>
<td>30</td>
<td>Irritability, abdominal distension, bloating, recurrent abdominal cramps, apathy, painful joints.</td>
<td>+</td>
<td>269.5 U</td>
<td>Marsh III</td>
</tr>
<tr>
<td>Mother</td>
<td>39</td>
<td>Painful joints, osteoporosis</td>
<td>+</td>
<td>175 U</td>
<td>Marsh III</td>
</tr>
</tbody>
</table>


v. 45 – no.1 – jan./mar. 2008 Arq Gastroenterol 71

RESUMO – Racional - Vários estudos têm evidenciado que a doença celíaca, afeição auto-imune que ocorre em indivíduos geneticamente suscetíveis, apresenta prevalência aumentada entre parentes de pacientes celíacos. Objetivo - Determinar a prevalência da doença celíaca em grupo de parentes de primeiros graus de pacientes celíacos brasileiros. Métodos - Parentes de primeiro grau de pacientes celíacos atendidos no Ambulatório de Gastroenterologia Pediátrica do Hospital Universitário de Brasília e no Centro de Pesquisas da Doença Celíaca da Faculdade de Medicina da Universidade de Brasília entre março de 2001 e novembro de 2004 foram testados para detectar a possibilidade de anticorpos anti-endoemniso (IgA-EMA). Todos os soros IgA-EMA positivos foram submetidos a segundo teste confirmando a sua positividade sorológica pela presença de anticorpos anti-transglutaminase (IgA-tTG). Biopsias jejuna ou duodenais foram efetuadas em todos os indivíduos com sorologia positiva. As amostras de mucosa foram histologicamente classificadas de acordo com a classificação de Marsh em tipo (0) normal, (I) infiltrativa, (II) hiperplásica infiltrativa, (III) destrutiva plana e (IV) hipoplasia atrófica. O diagnóstico conclusivo foi firmado com base na positividade dos testes sorológicos e na presença de lesões intestinais de grau de I a III. Resultados - Nove novos casos de doença celíaca foram detectados dentre os 188 parentes de primeiro grau de pacientes celíacos (4,8%). Conclusão - Confirma-se a alta prevalência de doença celíaca entre parentes de primeiro grau de celíacos e reforça-se a necessidade de investigação diagnóstica rotineira deste grupo específico de indivíduos.


REFERENCES